口腔医学研究

口腔医学研究 ›› 2022, Vol. 38 ›› Issue (1): 80-84.DOI: 10.13701/j.cnki.kqyxyj.2022.01.017

• 口腔黏膜病学研究 • 上一篇    下一篇

重组人表皮生长因子外用溶液联合重组人粒细胞刺激因子治疗化疗所致口腔黏膜炎的效果

王知刚, 张波*   

  1. 风湿性疾病发生与干预湖北省重点实验室(湖北民族大学),湖北民族大学附属民大医院口腔医学中心 湖北 恩施 445000
  • 收稿日期:2021-06-11 出版日期:2022-01-28 发布日期:2022-01-21
  • 通讯作者: * 张波,E-mail: zyyydcg@163.com
  • 作者简介:王知刚(1987~ ),男,湖北恩施人,硕士,主治医师,研究方向:牙周黏膜疾病。
  • 基金资助:
    湖北省自然科学基金项目(编号:2019CFB816);风湿性疾病发生与干预湖北省重点实验室项目(编号:OIR20006A);湖北民族大学博士启动基金项目(编号:MD2020B016);湖北省卫生健康科研基金项目(编号:WJ2019H142);恩施州科技计划重点项目(编号:XYJ2020000059)

Effect of Recombinant Human Epidermal Growth Factor Topical Solution Combined with Recombinant Human Granulocyte Stimulating Factor on the Treatment of Chemotherapy-induced Oral Mucositis

WANG Zhigang, ZHANG Bo*   

  1. Hubei Provincial Key Laboratory of Occurrence and Intervention of Rheumatic Diseases, Department of Stomatology, Minda Hospital, Hubei Minzu University, Enshi 445000, China
  • Received:2021-06-11 Online:2022-01-28 Published:2022-01-21

PDF (PC)

261

摘要： 目的:探讨重组人表皮生长因子外用溶液联合重组人粒细胞刺激因子(recombinant human granulocyte stimulating factor, RHGSF)治疗化疗所致口腔黏膜炎的效果及对患者血管内皮生长因子的影响。方法:选取2019年12月~2020年12月我院收治的化疗所致口腔黏膜炎患者94例,随机分为对照组和研究组各47例,对照组应用重组人表皮生长因子外用溶液治疗,研究组应用重组人表皮生长因子外用溶液联合RHGSF治疗。观察分析两组患者的临床疗效、口腔pH值、VAS评分、血清HIF-1α、VEGF水平情况。结果:治疗后,研究组临床疗效(95.74%)明显高于对照组(76.60%),差异具有统计学意义(P＜0.05);治疗前两组VAS评分差异无统计学意义(P＞0.05),治疗后研究组VAS评分低于对照组,差异具有统计学意义(P＜0.05);治疗前,两组口腔PH值差异无统计学意义(P＞0.05),治疗后研究组口腔PH值低于对照组,差异具有统计学意义(P＜0.05);治疗后,研究组血清HIF-1α的平均水平为(4.8±1.1) ng/L,血清VEGF的平均水平为(29.1±3.2) ng/L。对照组血清HIF-1α的平均水平为(6.1±1.2) ng/L,血清VEGF的平均水平为(19.7±3.4) ng/L。研究组血清HIF-1α水平低于对照组,研究组VEGF水平高于对照组,差异具有统计学意义(P＜0.05)。结论:化疗所致口腔黏膜炎患者应用重组人表皮生长因子外用溶液联合RHGSF治疗效果显著,可以降低其口腔PH值和疼痛程度,减少HIF-1α和增加VEGF在机体内的浓度。

关键词: 重组人表皮生长因子外用溶液, 重组人粒细胞刺激因子, 口腔黏膜炎, 血管内皮生长因子

Abstract: Objective: To investigate the effect of recombinant human epidermal growth factor (EGF) combined with recombinant human granulocyte stimulating factor (GSF) on oral mucositis induced by chemotherapy. Methods: A total of 94 patients with oral mucositis caused by chemotherapy admitted to our hospital from December 2019 to December 2020 were randomly divided into control group and study group, with 47 cases in each group. The control group was treated with recombinant human EGF external solution, and the study group was treated with recombinant human EGF external solution combined with GSF. Clinical efficacy, oral PH value, VAS score, serum HIF-1α, and VEGF were observed and analyzed. Results: After treatment, the clinical efficacy of the study group (95.74%) was significantly higher than that of the control group (76.60%, P<0.05). There were no significant differences in the VAS score and oral pH between two groups before treatment (P>0.05), however, after treatment, the VAS score and oral pH of the study group were lower than those of the control group (P<0.05). The serum HIF-1α level of the study group [(4.8±1.1) ng/L] was lower than that of the control group [(6.1±1.2) ng/L, P<0.05], and the VEGF level of the study group [(29.1±3.2) ng/L] was higher than that of the control group [(19.7±3.4) ng/L, P<0.05]. Conclusion: Recombinant human EGF external solution combined with GSF is effective in the treatment of oral mucositis caused by chemotherapy, which can reduce the oral PH, pain, and HIF-1α, and increase VEGF in the body.

Key words: recombinant human epidermal growth factor external solution, recombinant human granulocyte stimulating factor, oral mucositis, vascular endothelial growth factor